## Supporting Information

# Nose-to-brain drug delivery by HS15 micelles for Brain Targeting of insoluble drug 

Wei Zhang ${ }^{\text {a }}$, Long Wan ${ }^{\text {b }}$, Meiqi Han $^{\text {c }}$, Wen Guo ${ }^{\text {a }}$, Zhiqi Wang ${ }^{\text {a }}$, Xinyue Zhang ${ }^{\text {a }}$ Xuyang Liu ${ }^{\text {a }}$, Jiahao Wang ${ }^{\text {a }}$, Yuling Mao ${ }^{\mathrm{a}^{*}}$
${ }^{\text {a }}$ Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province 110016, China
${ }^{\mathrm{b}}$ Department of Pharmacy, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, Liaoning, China
${ }^{c}$ Department of Microbiology and Biochemical Pharmacy, School of Medical Devices, Shenyang Pharmaceutical University, Shenyang 110016, China

## The corresponding author*

Yuling Mao

E-mail address: maoyuling@syphu.edu.cn

Table S1 The particle sizes of HS15-AGO respectively with CSF and PBS solution.

|  | In Cerebrospinal Fluid <br> $(\mathrm{CSF})(\mathrm{nm})$ |  | In Phosphate buffered saline <br> $(\mathrm{PBS})(\mathrm{nm})$ |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1.0 | 13.31 | 12.92 | 13.02 | 14.17 | 13.90 | 13.69 |
| 2.0 | 13.34 | 13.94 | 14.00 | 14.05 | 13.76 | 14.89 |
| 6.0 | 14.05 | 13.76 | 14.89 | 14.82 | 14.04 | 14.60 |
| 10.0 | 16.21 | 15.43 | 14.78 | 14.17 | 17.85 | 14.17 |
| 14.0 | 17.85 | 14.83 | 15.29 | 15.81 | 14.99 | 15.40 |
| 24.0 | 19.13 | 19.36 | 16.17 | 16.63 | 16.06 | 15.35 |

Table S2 The vitro release data of HS15-AGO in NF and CSF.

|  | In Nasal Fluid (NF) (\%) |  | In Cerebrospinal Fluid (CSF) (\%) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.5 h | 41.0 | 43.4 | 39.5 | 38.9 | 36.8 | 39.4 |
| 1.0 h | 61.0 | 60.8 | 58.4 | 51.0 | 50.2 | 52.4 |
| 2.0 h | 71.8 | 72.6 | 70.6 | 72.9 | 73.3 | 75.1 |
| 4.0 h | 93.7 | 95.0 | 93.7 | 91.7 | 91.6 | 93.2 |
| 6.0 h | 96.2 | 100.3 | 97.3 | 96.3 | 96.1 | 97.6 |
| 8.0 h | 99.1 | 98.3 | 95.8 | 102.5 | 102.3 | 104.0 |
| 10.0 h | 101.9 | 101.2 | 99.5 | 100.9 | 100.0 | 102.7 |

Table S3 The vitro release data of AGO in NF and CSF.

|  | In Nasal Fluid (NF) (\%) |  |  | In Cerebrospinal Fluid (CSF)(\%) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.5 h | 53.1 | 54.1 | 49.9 | 45.7 | 44.5 | 44.8 |
| 1.0 h | 67.7 | 66.9 | 68.5 | 70.2 | 71.4 | 68.2 |
| 2.0 h | 97.9 | 96.1 | 99.6 | 94.6 | 96.2 | 92.1 |
| 4.0 h | 102.3 | 101.4 | 102.4 | 102.9 | 98.3 | 96.5 |
| 6.0 h | 103.0 | 101.7 | 105.3 | 105.6 | 104.6 | 102.2 |
| 8.0 h | 104.6 | 100.6 | 106.0 | 109.5 | 108.7 | 107.5 |
| 10.0 h | 107.2 | 102.9 | 108.8 | 110.4 | 109.7 | 108.8 |

